Performance has declin After this transaction, the company will fully integrate with the target company to ensure the target company’s market competitiveness and longterm stable development capabilities.
However, if there are adverse changes in the target company’s future operating activities, the goodwill
will be at risk of impairment and will have an adverse st. pierre and miquelon email list 100000 contact leads impact on the company’s future current profit and loss.
Dai Lizhong, Chairman of Shengxiang Bio, said that efficient integration and personalization of
prevention, diagnosis and treatment is the inevitable trend of proactive health, and is also the direction
of Shengxiang Bio’s innovation and exploration in the new era of life science.
The strong alliance between Shengxiang Bio and Zhongshan Haiji will leverage the resource
advantages of precision diagnosis and biomanufacturing, which will help create an integrat health solution for piatric diagnosis and treatment.
Before this merger and acquisition
Shengxiang Bio ‘s attributable net profit had declin for three consecutive years from 2021 to 2023 .
Data shows that from 2020 to 2023, Shengxiang Bio achiev revenues of 4.763 billion yuan, 4.515
billion yuan, 6.45 billion yuan and 1.007 billion yuan, respectively; among which the fullyear operating
income in 2023 show a sharp decline; from 2020 to 2023, the company ‘s attributable net profits were
2.617 billion yuan, 2.243 billion yuan, 1.937 billion yuan and 364 million yuan, respectively.
In the first three quarters of 2024, Shengxiang while both approaches have their benefits Bio’s attributable net profit also declin. During the
reporting period, the company achiev operating income of 1.033 billion yuan, a yearonyear increase of
63.24%; the corresponding attributable net profit was 195 million yuan, a yearonyear decrease of 34.8%.
In order to ruce its dependence on the sales
Of new coronavirus nucleic acid testing reagents and instruments , in 2022, Shengxiang Bio propos “second entrepreneurship” to find new growth points.
On May 9, 2023, the company announc that it plans to liechtenstein number jointly invest with its relat parties to establish
Hunan Shengxiang Ansai Biotechnology Co., Ltd. to further improve the company’s comprehensive strategic layout in the field of immunodiagnosis, especially chemiluminescence Performance has declin.